Please assess the completion status of the following clinical trial:

Trial Title: Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with history of mild atopic asthma between 18 and 60 years-of-age~* Body mass index (BMI) between 18 and 35 kg/m\^2~* Normal or clinically acceptable physical examination (PE), clinical laboratory values, and electrocardiogram (ECG); clinically acceptable PE includes history of mild atopic asthma~* Used only inhaled short-acting β2-agonists infrequently to treat asthma~* No current exposure to allergens to which subject experiences asthmatic responses~* No other lung disease, exacerbations of asthma or lower respiratory tract infections for at least 6 weeks prior to screening~* Positive skin prick test to common aeroallergens at screening~* Additional inclusion criteria apply~Exclusion Criteria:~* History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;~* History or current medical conditions that are contraindicated for methacholine challenge, such as myocardial infarction or stroke within previous 3 months, known cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm~* Evidence of active or suspected bacterial, viral, fungal or parasitic infections within past 6 weeks~* Subject has know type I/II diabetes~* History of residential exposure to tuberculosis or has a positive purified protein derivative (PPD) or QuantiFERON test within 4 weeks before randomization~* Subject who has history of malignancy of any type within 5 years prior to enrollment~* Subjects tested positive for drugs/alcohol or nicotine use at screening~* Subjects tested positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C~* Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to tezepelumab administered by intravenous infusion on study days 1, 29, and 57.
- Tezepelumab 700 mg (Type: EXPERIMENTAL): Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57.

Based on this trial design, predict the completion outcome and termination type (if applicable).